COVID-19患者需要更长的体外膜氧合支持才能存活,与非COVID-19患者相比
该研究为单中心ICU的初步分析,数据来自两项前瞻性ECMO试验及一个回顾性ARDS ECMO队列。纳入16例COVID-19与23例非COVID-19成人ARDS ECMO患者,两组基础疾病与体重指数无差异。COVID-19 ECMO患者ICU存活率为62%,非COVID-19为70%;存活者ECMO支持中位时间分别为43天与16天(p=0.03)。2007—2018年全部ARDS ECMO患者中位支持15天,病毒性肺炎亚组16天,流感肺炎存活者13天。结论认为COVID-19患者需要显著更长的ECMO支持才能成功脱机并存活出ICU。
要点
- COVID-19相关ARDS的ECMO存活者中位支持43天(IQR 18-58天),非COVID-19存活者16天(IQR 19-39天),p=0.03。
- COVID-19 ECMO患者ICU存活率62%,非COVID-19 ECMO患者70%。
- 两组在基础疾病与体重指数方面无差异。
- 2007—2018年全部ARDS ECMO患者中位支持15天(IQR 6-28天);病毒性肺炎亚组16天(IQR 9-27天),流感肺炎存活者13天(IQR 7-25天)。
适用人群与场景
- 单中心ICU的成人ARDS ECMO患者,16例COVID-19与23例非COVID-19患者;另分析346例成人ARDS ECMO患者的回顾性数据。
研究设计与关键结果
- 研究类型:两项前瞻性ECMO试验数据的初步分析,加上一个ARDS ECMO患者队列的回顾性分析;单中心ICU;16例COVID-19 vs 23例非COVID-19成人ARDS ECMO患者。
- COVID-19与COVID-19 ARDS患者在基础疾病和体重指数方面无差异。
- ICU存活率:COVID-19 ECMO患者62%,非COVID-19 ECMO患者70%。
- COVID-19 ECMO存活者中位ECMO支持43天(IQR 18-58天),非COVID-19患者16天(IQR 19-39天),p=0.03(原文此处非COVID-19组IQR下界19大于上界16,原文此处表述有矛盾)。
- 2007—2018年全部ARDS ECMO患者中位ECMO治疗时间15天(IQR 6-28天)。
- 任何病毒性肺炎亚组中位ECMO支持16天(IQR 9-27天),流感肺炎存活者13天(IQR 7-25天)。
证据类型、等级与局限
- 证据类型:两项前瞻性ECMO试验数据的初步分析及回顾性队列分析;单中心。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,与非COVID-19患者相比,COVID-19患者需要显著更长的ECMO支持才能实现成功脱机和ICU存活。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: To investigate the ICU survival of venovenous extracorporeal membrane oxygenation (ECMO) patients suffering from COVID-19-related acute respiratory distress syndrome (ARDS) versus ECMO patients without COVID-19 (non-COVID-19)-related ARDS.
DESIGN: Preliminary analysis of data from two prospective ECMO trials and retrospective analysis of a cohort of ARDS ECMO patients.
SETTING: Single-center ICU.
PATIENTS: Adult ARDS ECMO patients, 16 COVID-19 versus 23 non-COVID-19 patients. Analysis of retrospective data from 346 adult ARDS ECMO patients.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: COVID-19 and non-COVID-19 ARDS patients did not differ with respect to preexisting disease or body mass index. ICU survival rate was 62% for COVID-19 ECMO patients and 70% for non-COVID-19 ECMO patients. COVID-19 ECMO survivors were supported with ECMO for a median of 43 days (interquartile range [IQR], 18-58 d) versus 16 days (IQR, 19-39 d; p = 0.03) for non-COVID-19 patients. The median duration of ECMO therapy for all ARDS patients between 2007 and 2018 was 15 days (IQR, 6-28 d). The subgroup of patients suffering from any viral pneumonia received ECMO support for a median of 16 days (IQR, 9-27 d), survivors of influenza pneumonia received ECMO support for 13 days (IQR, 7-25 d).
CONCLUSIONS: COVID-19 patients required significant longer ECMO support compared with patients without COVID-19 to achieve successful ECMO weaning and ICU survival.
参考来源
- Russ M, Menk M, Graw JA, et al. COVID-19 Patients Require Prolonged Extracorporeal Membrane Oxygenation Support for Survival Compared With Non-COVID-19 Patients. Crit Care Explor. 2022. PMID: 35372842. doi:10.1097/CCE.0000000000000671
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。